|
|
|||
| |||||||||||||||||||||||||||||||
The coming of age of modern hematopathology began in the 1970s, largely as a result of key discoveries in basic immunology. These findings led to the seminal concept that malignant lymphomas could be characterized as neoplasms that developed from defined cells of the lymphoreticular system. Over the next two decades, applications of monoclonal-antibody technology, molecular biology, and cytogenetics further revolutionized approaches to the diagnosis, classification, and treatment of malignant lymphomas and other hematopoietic neoplasms. Although these advances have illuminated our knowledge of the pathobiology of these tumors, they have also resulted in an enormous and often confusing literature published in
HOME | SUBSCRIBE | SEARCH | CURRENT ISSUE | PAST ISSUES | COLLECTIONS | PRIVACY | HELP | beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved. |